Simply Wall St.
Assessing Insmed (INSM) Valuation After Strong One Year Return And Recent Share Price Pullback
📊
AI Sentiment
Positive
6/10
- Home
- INSM
INSM
Insmed Incorporated
as of 02-17-2026 10:31am EST
$150.32
+$1.57
+1.06%
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Upcoming Earnings Alert:
Get ready for potential market movements as Insmed Incorporated (INSM) prepares to release earnings report on 19 Feb 2026.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 31.2B | IPO Year: | 2000 |
| Target Price: | $192.27 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 24 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $60.40 - $212.75 | Next Earning Date: | 02-19-2026 |
| Revenue: | $447,022,000 | Revenue Growth: | 30.34% |
| Revenue Growth (this year): | 57.54% | Revenue Growth (next year): | 141.54% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -906141000.0 | FCF Growth: | N/A |
AI-Powered INSM Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 16 hours ago
AI Recommendation
hold
Model Accuracy: 73.25%
73.25%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Insmed Incorporated (INSM)
Lewis William
Sell
Chair and CEO
INSM Feb 9, 2026
Avg Cost/Share
$148.01
Shares
13,396
Total Value
$1,979,763.59
Owned After
309,693
Flammer Martina M.D.
Sell
Chief Medical Officer
INSM Feb 5, 2026
Avg Cost/Share
$152.44
Shares
869
Total Value
$132,470.36
Owned After
83,243
SEC Form 4
Lewis William
Sell
Chair and CEO
INSM Feb 3, 2026
Avg Cost/Share
$156.34
Shares
3,009
Total Value
$470,427.06
Owned After
309,693
SEC Form 4
Flammer Martina M.D.
Sell
Chief Medical Officer
INSM Feb 3, 2026
Avg Cost/Share
$155.77
Shares
795
Total Value
$123,837.15
Owned After
83,243
SEC Form 4
Bonstein Sara
Sell
Chief Financial Officer
INSM Feb 3, 2026
Avg Cost/Share
$156.34
Shares
748
Total Value
$116,942.32
Owned After
79,758
SEC Form 4
Adsett Roger
Sell
Chief Operating Officer
INSM Feb 3, 2026
Avg Cost/Share
$156.17
Shares
791
Total Value
$123,530.47
Owned After
106,810
SEC Form 4
Smith Michael Alexander
Sell
Chief Legal Officer
INSM Feb 3, 2026
Avg Cost/Share
$156.27
Shares
640
Total Value
$100,012.80
Owned After
56,397
SEC Form 4
Flammer Martina M.D.
Sell
Chief Medical Officer
INSM Feb 2, 2026
Avg Cost/Share
$154.42
Shares
7,982
Total Value
$1,233,959.02
Owned After
83,243
Lewis William
Sell
Chair and CEO
INSM Jan 20, 2026
Avg Cost/Share
$158.94
Shares
10,699
Total Value
$1,700,411.49
Owned After
309,693
Lewis William
Sell
Chair and CEO
INSM Jan 12, 2026
Avg Cost/Share
$170.67
Shares
19,215
Total Value
$3,247,348.91
Owned After
309,693
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Lewis William | INSM | Chair and CEO | Feb 9, 2026 | Sell | $148.01 | 13,396 | $1,979,763.59 | 309,693 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Feb 5, 2026 | Sell | $152.44 | 869 | $132,470.36 | 83,243 | |
| Lewis William | INSM | Chair and CEO | Feb 3, 2026 | Sell | $156.34 | 3,009 | $470,427.06 | 309,693 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Feb 3, 2026 | Sell | $155.77 | 795 | $123,837.15 | 83,243 | |
| Bonstein Sara | INSM | Chief Financial Officer | Feb 3, 2026 | Sell | $156.34 | 748 | $116,942.32 | 79,758 | |
| Adsett Roger | INSM | Chief Operating Officer | Feb 3, 2026 | Sell | $156.17 | 791 | $123,530.47 | 106,810 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | Feb 3, 2026 | Sell | $156.27 | 640 | $100,012.80 | 56,397 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Feb 2, 2026 | Sell | $154.42 | 7,982 | $1,233,959.02 | 83,243 | |
| Lewis William | INSM | Chair and CEO | Jan 20, 2026 | Sell | $158.94 | 10,699 | $1,700,411.49 | 309,693 | |
| Lewis William | INSM | Chair and CEO | Jan 12, 2026 | Sell | $170.67 | 19,215 | $3,247,348.91 | 309,693 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
Simply Wall St.
Does Insmed (INSM) Still Look Attractive After Recent Share Price Pullback?
📈
AI Sentiment
Highly Positive
8/10
Motley Fool
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
📈
AI Sentiment
Highly Positive
9/10
Motley Fool
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million
📈
AI Sentiment
Highly Positive
9/10
Zacks
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Possible Bearish Signals With Insmed Insiders Disposing Stock
📉
AI Sentiment
Negative
3/10
MT Newswires
Insmed Insider Sold Shares Worth $1,979,764, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
Compare INSM vs Leading Stocks
See how INSM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.